Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin

Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vonkeman, Harald, Meek, Inger, van de Laar, Mart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108704/
https://www.ncbi.nlm.nih.gov/pubmed/21701631
http://dx.doi.org/10.2147/DHPS.S7206
_version_ 1782205356401754112
author Vonkeman, Harald
Meek, Inger
van de Laar, Mart
author_facet Vonkeman, Harald
Meek, Inger
van de Laar, Mart
author_sort Vonkeman, Harald
collection PubMed
description Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects, identify the risk factors involved, and provide an overview of preventive strategies, thereby focusing on the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin.
format Online
Article
Text
id pubmed-3108704
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31087042011-06-23 Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin Vonkeman, Harald Meek, Inger van de Laar, Mart Drug Healthc Patient Saf Review Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects, identify the risk factors involved, and provide an overview of preventive strategies, thereby focusing on the rationale and clinical utility of combining proton-pump inhibitors with low-dose aspirin. Dove Medical Press 2010-10-06 /pmc/articles/PMC3108704/ /pubmed/21701631 http://dx.doi.org/10.2147/DHPS.S7206 Text en © 2010 Vonkeman et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Vonkeman, Harald
Meek, Inger
van de Laar, Mart
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title_full Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title_fullStr Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title_full_unstemmed Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title_short Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
title_sort risk management of risk management: combining proton pump inhibitors with low-dose aspirin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108704/
https://www.ncbi.nlm.nih.gov/pubmed/21701631
http://dx.doi.org/10.2147/DHPS.S7206
work_keys_str_mv AT vonkemanharald riskmanagementofriskmanagementcombiningprotonpumpinhibitorswithlowdoseaspirin
AT meekinger riskmanagementofriskmanagementcombiningprotonpumpinhibitorswithlowdoseaspirin
AT vandelaarmart riskmanagementofriskmanagementcombiningprotonpumpinhibitorswithlowdoseaspirin

Ejemplares similares